Jamil Asselah - Hepato-Pancreato-Biliary and Transplant Surgery, McGill University Health Center

基本信息

浏览量：51

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 31 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

PCR191 Patient-Centric Assessment of Treatment Experience in Breast Cancer: Development and Validation of a Patient Questionnaire

K. Gurjar, B. Rattanavong,L. Bennetts, J. Sahota, M. Ouerghi,C. Ammendolea,J. Asselah, S. Bartlett,C. Brezden-Masley,J. Croke,T. Hijal,J. Kildea,J. Papadakos, L. Watson,D. Soliman

Value in Healthno. 6 (2024): S331-S331

引用0浏览0引用

159Tip TROPION-Breast04: Phase (ph) III Study of Neoadjuvant (neoadj) Datopotamab Deruxtecan (Dato-Dxd) + Durvalumab (D) Followed by Adjuvant (adj) D Vs Standard of Care (soc) in Treatment-Naïve, Triple-Negative (TN) and HR-low/HER2- Breast Cancer (BC)

S. Loibl,S.M. Tolaney, P. Schmid, B. Pistilli,R.A. Dent,J. Asselah, Q. Liu, J.L. Meisel,N. Niikura,Y.H. Park,G. Werutsky,G. Bianchini, J.C. Andersen,R. Kozarski,N. Rokutanda,H.L. McArthur

ESMO Open (2024): 103146

引用0浏览0引用

379MO Datopotamab Deruxtecan (Dato-Dxd) + Durvalumab (D) As First-Line (1L) Treatment for Unresectable Locally Advanced/metastatic Triple-Negative Breast Cancer (a/mtnbc): Updated Results from BEGONIA, a Phase Ib/II Study

P. Schmid,P.J. Wysocki,C.X. Ma,Y.H. Park,R. Fernandes,S. Lord,R.D. Baird,C. Prady,K.H. Jung,J. Asselah,R. Huisden,R. Stewart,K. Heider,P. Vukovic,N. Denduluri,Z. Nowecki

Annals of Oncology (2023): S337

引用18浏览0引用

Datopotamab Deruxtecan (Dato-Dxd) Plus Durvalumab (D) As First-Line (1L) Treatment for Unresectable Locally Advanced/metastatic Triple-Negative Breast Cancer (a/mtnbc): Updated Results from BEGONIA, a Phase Ib/II Study

P. Schmid,P. J. Wysocki,C. X. Ma, H. Park,R. Fernandes,S. Lord,R. D. Baird,C. Prady,K. H. Jung,J. Asselah,R. Huisden,R. Stewart,K. Heider,P. Vukovic,N. Denduluri,Z. Nowecki

ANNALS OF ONCOLOGY（2023）

引用27浏览0引用

137P Combining Protein and Mrna Spatial Profiles to Identify Distinct Cell Population in Metaplastic Breast Cancer

H. Kuasne,P. Savage, B. Khadang, J. Lai,C. Martinez Ramirez,A. Monast,A-M. Fortier, S. Busque,J. Asselah,N. Bouganim,S. Meterissian,A. Omeroglu,M. Basik,Y. Riazalhosseini,M. Park

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

364 IMPACT ON SURGICAL AND ONCOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY VERSUS SURGERY ALONE IN ELDERLY PATIENTS WITH LOCALLY INVASIVE GASTROESOPHAGEAL CANCER

A Antoun,A Kammili,H Naghawi,T Alcindor,J Asselah,M Vanhuyse,J Cools-Lartigue,L Ferri,C Mueller

Diseases of the Esophagus（2020）

引用0浏览0引用

153P the Systemic Inflammation Response Index (SIRI) is a Prognostic Factor That Correlates with Tumor Burden in Advanced Pancreatic Cancer

V. E. Pacheco-Barcia, T. France,J. Asselah,R. Mondejar,G. Zogopoulos,R. Serrano,O. Donnay,J. Rogado,L. Del Campo,E. Martinez,E. Martin, C. Arlanzon,P. Ochoa,K. Guo, G. Barrena,R. Colomer Bosch

Annals of Oncology（2020）

引用0浏览0引用

Interim Analysis of a Phase II Trial of Perioperative Chemotherapy Plus Avelumab in Esophagogastric and Gastric Adenocarcinoma

T. Alcindor,T. Opu,C. Mueller,V. Marcus,P-O. Fiset,S. Camilleri-Broet,G. Artho,J. Asselah,M. Vanhuyse,M. Hickeson,A. Awan, Z. Koulouris,L. Ferri

ANNALS OF ONCOLOGY（2019）

引用2浏览0引用

A Systemic Inflammation Response Index (SIRI) Correlates with Survival and Could Be a Predictive Factor for Mfolfirinox in Metastatic Pancreatic Cancer (PC)

V. E. Pacheco-Barcia,R. Mondejar, T. France,J. Asselah,O. Donnay,G. Zogopoulos,N. Bouganim,K. Guo,E. Martin,T. Alcindor,R. Colomer Bosch

ANNALS OF ONCOLOGY（2019）

引用0浏览0引用

Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival

V. Pacheco-Barcia, T. France,G. Zogopoulos,N. Bouganim,O. Donnay,T. Alcindor,R. Mondéjar Solís,K. Guo,E. Martin,R. Colomer,J. Asselah

Annals of Oncology (2018): v46

引用4浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn